P53 gene: Mutation and immunohistochemical analysis in patients with invasive ductal carcinoma of breast

被引:0
作者
机构
[1] Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi
[2] Department of Biochemistry, Banaras Hindu University, Varanasi
[3] Cancer Research Institute, N. E. Railways, Lehertara, Varanasi
[4] Department of Pathology, Cancer Research Institute, N. E. Railways, Lehertara, Varanasi
[5] Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, Varanasi
来源
Singh, S. | 1600年 / Science Publications卷 / 09期
关键词
Breast cancer; ER; HER2; p53; PR;
D O I
10.3844/ajbbsp.2013.395.403
中图分类号
学科分类号
摘要
The p53 tumor suppressor gene is the most commonly mutated gene in cancer. In breast cancer, the presence of p53 gene alterations has been associated with worse prognosis. This study was attempted to associate p53 gene mutations with its protein expression in North Eastern Indian population. We used single-stranded conformation polymorphism to screen samples for mutations in five conserved regions, exons 4, 5, 6, 7 and 8, of the p53 gene. Mutations were confirmed by direct DNA sequencing. Samples were also analyzed for expression of p53 immunohistochemically. We found two critical mutations in the exon 4. A well known missense mutation at codon 72 (pro to arg) with a frequency of 47% was found which was significantly correlated with the immunohistochemical analysis of p53 protein in such patients. A novel nonsense mutation at codon 107 which leads to stop codon was also found. Although the occurrence of this mutation was very less, we did not find expression of p53 protein immunohistochemicaly. We support that mutation in p53 gene can be exploited as a prognostic marker for the early diagnosis of breast cancer, although more clinical and epidemiological data is required to establish this claim. © 2013 Science Publication.
引用
收藏
页码:395 / 403
页数:8
相关论文
共 41 条
  • [1] Allred D.C., Bustamante M.A., Daniel C.O., Immunocytochemical analysis of estrogen receptors in human breast carcinomas: Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance, Arch. Surg, 125, pp. 107-113, (1990)
  • [2] Anne-Lise B., TP53 and breast cancer, Hum Mutat, 21, pp. 292-300, (2003)
  • [3] Badwe R.A., Gangawal S., Mittra I., Desai P.B., Clinico-pathological features and prognosis of breast cancer in different religious communities in India, Indian J. Cancer, 27, pp. 220-228, (1990)
  • [4] Baum M., The changing face of breast cancer--past, present and future perspectives, Breast Cancer Res. Treat, 75, (2002)
  • [5] Bourn D., Carter S.A., Mason S., Gareth D., Evans R., Et al., Germline mutations in the neurofibromatosis type 2 tumour suppressor gene, Hum. Mol. Genet, 3, pp. 813-816, (1994)
  • [6] Buyru N., Tigli H., Dalay N., P53 codon 72 polymorphism in breast cancer, Oncol. Rep, 10, pp. 711-714, (2003)
  • [7] Chosdol K., Ahuja A., Rathore A., Anjan M., Syed H.M., Et al., Study of p53 codon 72 polymorphism in various ethnic groups of North India, Curr. Sci, 82, pp. 1253-1255, (2002)
  • [8] Cutler W.B., Burki R.E., Genovesse E., Penn F., Zacher M.G., Et al., Breast cancer in postmenopausal women: What is the real risk?, Fertil Steril, 92, (2009)
  • [9] Dako, Hoffman F., Hercep Test Interpretation Manual-Breast, (2002)
  • [10] Dupont W.D., Page D.L., Risk factors for breast cancer in women with proliferative breast disease, N. Engl. J. Med, 312, pp. 146-151, (1985)